AgomAb Therapeutics NV

AGMB · Figures in euros

About AgomAb Therapeutics NV

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

agomab.com ↗

Employees: 62
Listed: Nasdaq · AGMB

Income statement

Revenue, gross profit and net income

Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Cash flow

Operating and free cash flow

Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Stock-based compensation

Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.

Stock-based compensation